We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A company making cancer treatments is disputing a warning letter from the FDA that claims the firm’s manufacturing process falls under its regulations, but a former FDA official says the company has little chance of prevailing.